Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin (incobotulinumtoxinA, NT 201) for the Treatment of Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy

Next Previous
X
Search
Trial Profile

Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin (incobotulinumtoxinA, NT 201) for the Treatment of Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Muscle spasticity
  • Focus Registrational; Therapeutic Use
  • Acronyms TIM
  • Sponsors Merz Pharmaceuticals GmbH

    • Most Recent Events

    • 22 Sep 2021 Results of a pooled analysis assessing the neutralizing antibody (NAb) formation in three large Phase 3 studies ( NCT01905683, NCT01893411 and NCT02002884) presented at the 25th International Congress of Parkinson's Disease and Movement Disorders
    • 22 Sep 2021 Results of pooled analysis of two randomized Phase 3 studies, TIM (NCT01893411) and XARA (NCT02002884) assessing efficacy and safety of incobotulinumtoxinA for lower-limb (LL) and upper-limb (UL) spasticity in children and adolescents with cerebral palsy, presented at the 25th International Congress of Parkinson's Disease and Movement Disorders.
    • 22 Sep 2021 Results assessing effect of incobotulinumtoxinA on spasticity-related pain (SRP) using pooled data from three large Phase 3 pediatric studies (TIM (NCT01893411); TIMO (NCT01905683) & XARA (NCT02002884)) presented at the 25th International Congress of Parkinson's Disease and Movement Disorders.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top